Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Stable level of HIV transmitted drug resistance in Estonia despite significant scale-up of antiretroviral therapy.

Soodla P, Huik K, Pauskar M, Cuypers L, Van Laethem K, Rajasaar H, Kallas E, Lepa H, Velts-Lindh A, Jõgeda EL, Lutsar I, Avi R.

Infect Genet Evol. 2019 May 28:103901. doi: 10.1016/j.meegid.2019.05.019. [Epub ahead of print]

PMID:
31146045
2.

An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors.

Theys K, Libin PJK, Van Laethem K, Abecasis AB.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e00539-19. doi: 10.1128/AAC.00539-19. Print 2019 Aug.

PMID:
31109980
3.

Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium.

Vinken L, Fransen K, Cuypers L, Alexiev I, Balotta C, Debaisieux L, Seguin-Devaux C, García Ribas S, Gomes P, Incardona F, Kaiser R, Ruelle J, Sayan M, Paraschiv S, Paredes R, Peeters M, Sönnerborg A, Vancutsem E, Vandamme AM, Van den Wijngaert S, Van Ranst M, Verhofstede C, Stadler T, Lemey P, Van Laethem K.

Front Microbiol. 2019 Mar 26;10:613. doi: 10.3389/fmicb.2019.00613. eCollection 2019.

4.

Analysis of ex vivo HIV-1 infection in a controller-discordant couple.

Madlala P, Van de Velde P, Van Remoortel B, Vets S, Van Wijngaerden E, Van Laethem K, Gijsbers R, Schrijvers R, Debyser Z.

J Virus Erad. 2018 Jul 1;4(3):170-173.

5.

Phylogenetic analysis of the Belgian HIV-1 epidemic reveals that local transmission is almost exclusively driven by men having sex with men despite presence of large African migrant communities.

Verhofstede C, Dauwe K, Fransen K, Van Laethem K, Van den Wijngaert S, Ruelle J, Delforge ML, Vancutsem E, Vaira D, Stoffels K, Ribas SG, Dessilly G, Debaisieux L, Pierard D, Van Ranst M, Hayette MP, Deblonde J, Sasse A, Van Beckhoven D, Mortier V.

Infect Genet Evol. 2018 Jul;61:36-44. doi: 10.1016/j.meegid.2018.03.002. Epub 2018 Mar 6.

6.

Decision tree for accurate infection timing in individuals newly diagnosed with HIV-1 infection.

Verhofstede C, Fransen K, Van Den Heuvel A, Van Laethem K, Ruelle J, Vancutsem E, Stoffels K, Van den Wijngaert S, Delforge ML, Vaira D, Hebberecht L, Schauvliege M, Mortier V, Dauwe K, Callens S.

BMC Infect Dis. 2017 Nov 29;17(1):738. doi: 10.1186/s12879-017-2850-6.

7.

A18 Random amplification with next-generation sequencing to cover HIV and HCV full-length genomes.

Cuypers L, Conceição-Neto N, Dierickx T, Schrooten Y, Vrancken B, Van Wijngaerden E, Nevens F, Vandamme AM, Matthijnssens J, Van Laethem K.

Virus Evol. 2017 Mar 5;3(Suppl 1). pii: vew036.017. doi: 10.1093/ve/vew036.017. eCollection 2017 Mar. No abstract available.

8.

A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium.

Vinken L, Fransen K, Pineda-Peña AC, Alexiev I, Balotta C, Debaisieux L, Devaux C, García Ribas S, Gomes P, Incardona F, Kaiser R, Ruelle J, Sayan M, Paraschiv S, Paredes R, Peeters M, Sonnerborg A, Vancutsem E, Van den Wijngaert S, Van Ranst M, Verhofstede C, Vandamme AM, Lemey P, Van Laethem K.

Virus Evol. 2017 Mar 5;3(Suppl 1). pii: vew036.020. doi: 10.1093/ve/vew036.020. eCollection 2017 Mar. No abstract available.

9.

Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.

Cuypers L, Libin P, Schrooten Y, Theys K, Di Maio VC, Cento V, Lunar MM, Nevens F, Poljak M, Ceccherini-Silberstein F, Nowé A, Van Laethem K, Vandamme AM.

Infect Genet Evol. 2017 Sep;53:15-23. doi: 10.1016/j.meegid.2017.05.007. Epub 2017 May 9.

PMID:
28499845
10.

Phylogenetic evidence for underreporting of male-to-male sex among human immunodeficiency virus-infected donors in the Netherlands and Flanders.

van de Laar TJ, Bezemer D, van Laethem K, Vandewalle G, de Smet A, van Wijngaerden E, Claas EC, van Sighem AI, Vandamme AM, Compernolle V, Zaaijer HL.

Transfusion. 2017 May;57(5):1235-1247. doi: 10.1111/trf.14097. Epub 2017 Apr 4.

PMID:
28375576
11.

Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy.

Cuypers L, Vrancken B, Fabeni L, Marascio N, Cento V, Di Maio VC, Aragri M, Pineda-Peña AC, Schrooten Y, Van Laethem K, Balog D, Focà A, Torti C, Nevens F, Perno CF, Vandamme AM, Ceccherini-Silberstein F.

BMC Evol Biol. 2017 Mar 7;17(1):70. doi: 10.1186/s12862-017-0913-3.

12.

Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development.

Cuypers L, Li G, Neumann-Haefelin C, Piampongsant S, Libin P, Van Laethem K, Vandamme AM, Theys K.

Virus Evol. 2016 Sep 6;2(2):vew024. eCollection 2016 Jul.

13.

Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.

Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK.

Rev Med Virol. 2016 Nov;26(6):408-434. doi: 10.1002/rmv.1895. Epub 2016 Jul 12. Review.

PMID:
27401933
14.

Quantifying Next Generation Sequencing Sample Pre-Processing Bias in HIV-1 Complete Genome Sequencing.

Vrancken B, Trovão NS, Baele G, van Wijngaerden E, Vandamme AM, van Laethem K, Lemey P.

Viruses. 2016 Jan 7;8(1). pii: E12. doi: 10.3390/v8010012.

15.

Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.

Theys K, Van Laethem K, Gomes P, Baele G, Pineda-Peña AC, Vandamme AM, Camacho RJ, Abecasis AB.

AIDS Res Hum Retroviruses. 2016 May;32(5):427-33. doi: 10.1089/AID.2015.0095. Epub 2016 Jan 29.

16.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U.

Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

17.

Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure.

Theys K, Abecasis A, Libin P, Gomes PT, Cabanas J, Camacho RJ, Van Laethem K.

J Clin Virol. 2015 Sep;70:120-127. doi: 10.1016/j.jcv.2015.07.311. Epub 2015 Jul 29.

PMID:
26305833
18.

Disentangling the impact of within-host evolution and transmission dynamics on the tempo of HIV-1 evolution.

Vrancken B, Baele G, Vandamme AM, van Laethem K, Suchard MA, Lemey P.

AIDS. 2015 Jul 31;29(12):1549-56. doi: 10.1097/QAD.0000000000000731.

19.

Primary resistance to integrase strand-transfer inhibitors in Europe.

Casadellà M, van Ham PM, Noguera-Julian M, van Kessel A, Pou C, Hofstra LM, Santos JR, Garcia F, Struck D, Alexiev I, Bakken Kran AM, Hoepelman AI, Kostrikis LG, Somogyi S, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Staneková D, Stanojevic M, Van Laethem K, Zidovec Lepej S, Clotet B, Boucher CA, Paredes R, Wensing AM; SPREAD programme.

J Antimicrob Chemother. 2015 Oct;70(10):2885-8. doi: 10.1093/jac/dkv202. Epub 2015 Jul 17.

PMID:
26188038
20.

CRF19_cpx is an Evolutionary fit HIV-1 Variant Strongly Associated With Rapid Progression to AIDS in Cuba.

Kouri V, Khouri R, Alemán Y, Abrahantes Y, Vercauteren J, Pineda-Peña AC, Theys K, Megens S, Moutschen M, Pfeifer N, Van Weyenbergh J, Pérez AB, Pérez J, Pérez L, Van Laethem K, Vandamme AM.

EBioMedicine. 2015 Jan 28;2(3):244-54. doi: 10.1016/j.ebiom.2015.01.015. eCollection 2015 Mar.

21.

HIV-1 genotypic drug resistance testing: digging deep, reaching wide?

Van Laethem K, Theys K, Vandamme AM.

Curr Opin Virol. 2015 Oct;14:16-23. doi: 10.1016/j.coviro.2015.06.001. Epub 2015 Jun 24. Review.

PMID:
26114581
22.

Lack of evidence for the selection of E138 mutations by first-generation non-nucleoside reverse transcriptase inhibitors in patients infected with HIV-1 non-B subtypes.

Abecasis AB, van Laethem K, Theys K.

AIDS. 2015 May 15;29(8):987-8. doi: 10.1097/QAD.0000000000000627. No abstract available.

PMID:
25909833
23.

Performance of an in-house human immunodeficiency virus type 1 genotyping system for assessment of drug resistance in Cuba.

Alemán Y, Vinken L, Kourí V, Pérez L, Álvarez A, Abrahantes Y, Fonseca C, Pérez J, Correa C, Soto Y, Schrooten Y, Vandamme AM, Van Laethem K.

PLoS One. 2015 Feb 11;10(2):e0117176. doi: 10.1371/journal.pone.0117176. eCollection 2015.

24.

High frequency of antiviral drug resistance and non-b subtypes in HIV-1 patients failing antiviral therapy in Cuba.

Kouri V, Alemán Y, Pérez L, Pérez J, Fonseca C, Correa C, Aragonés C, Campos J, Alvarez D, Schrooten Y, Vinken L, Limia C, Soto Y, Vandamme AM, Van Laethem K.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19754. doi: 10.7448/IAS.17.4.19754. eCollection 2014.

25.

HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes.

Li G, Verheyen J, Theys K, Piampongsant S, Van Laethem K, Vandamme AM.

Retrovirology. 2014 Sep 25;11:79. doi: 10.1186/s12977-014-0079-7.

26.

Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.

Armitage AE, Deforche K, Welch JJ, Van Laethem K, Camacho R, Rambaut A, Iversen AK.

J Virol. 2014 Nov;88(21):12882-94. doi: 10.1128/JVI.01460-14. Epub 2014 Aug 27.

27.

Characterization of amino acids Arg, Ser and Thr at position 70 within HIV-1 reverse transcriptase.

Megens S, De Wit S, Bernatchez J, Dekeersmaeker N, Vinken L, Covens K, Theys K, Camacho RJ, Vandamme AM, Götte M, Van Laethem K.

Acta Clin Belg. 2014 Oct;69(5):348-57. doi: 10.1179/2295333714Y.0000000038. Epub 2014 Aug 7.

PMID:
25103592
28.

Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic.

Pineda-Peña AC, Schrooten Y, Vinken L, Ferreira F, Li G, Trovão NS, Khouri R, Derdelinckx I, De Munter P, Kücherer C, Kostrikis LG, Nielsen C, Littsola K, Wensing A, Stanojevic M, Paredes R, Balotta C, Albert J, Boucher C, Gomez-Lopez A, Van Wijngaerden E, Van Ranst M, Vercauteren J, Vandamme AM, Van Laethem K.

PLoS One. 2014 Jul 8;9(7):e101738. doi: 10.1371/journal.pone.0101738. eCollection 2014.

29.

Horizontal gene transfer from human host to HIV-1 reverse transcriptase confers drug resistance and partly compensates for replication deficits.

Megens S, Vaira D, De Baets G, Dekeersmaeker N, Schrooten Y, Li G, Schymkowitz J, Rousseau F, Vandamme AM, Moutschen M, Van Laethem K.

Virology. 2014 May;456-457:310-8. doi: 10.1016/j.virol.2014.03.023. Epub 2014 Apr 25.

30.

The genealogical population dynamics of HIV-1 in a large transmission chain: bridging within and among host evolutionary rates.

Vrancken B, Rambaut A, Suchard MA, Drummond A, Baele G, Derdelinckx I, Van Wijngaerden E, Vandamme AM, Van Laethem K, Lemey P.

PLoS Comput Biol. 2014 Apr 3;10(4):e1003505. doi: 10.1371/journal.pcbi.1003505. eCollection 2014 Apr.

31.

Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.

Swenson LC, Cobb B, Geretti AM, Harrigan PR, Poljak M, Seguin-Devaux C, Verhofstede C, Wirden M, Amendola A, Boni J, Bourlet T, Huder JB, Karasi JC, Zidovec Lepej S, Lunar MM, Mukabayire O, Schuurman R, Tomazic J, Van Laethem K, Vandekerckhove L, Wensing AM; International Viral Load Assay Collaboration.

J Clin Microbiol. 2014 Feb;52(2):517-23. doi: 10.1128/JCM.02461-13. Epub 2013 Dec 4.

32.

Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort.

Bartha I, Assel M, Sloot PM, Zazzi M, Torti C, Schülter E, De Luca A, Sönnerborg A, Abecasis AB, Van Laethem K, Rosi A, Svärd J, Paredes R, van de Vijver DA, Vandamme AM, Müller V.

BMC Infect Dis. 2013 Nov 12;13:537. doi: 10.1186/1471-2334-13-537.

33.

Evaluation of the automatic editing tool RECall for HIV-1 pol and V3 loop sequences.

Vinken L, Megens S, Schrooten Y, Vandamme AM, Van Laethem K.

J Virol Methods. 2013 Oct;193(1):135-9. doi: 10.1016/j.jviromet.2013.05.017. Epub 2013 Jun 5.

PMID:
23748120
34.

RegaDB: community-driven data management and analysis for infectious diseases.

Libin P, Beheydt G, Deforche K, Imbrechts S, Ferreira F, Van Laethem K, Theys K, Carvalho AP, Cavaco-Silva J, Lapadula G, Torti C, Assel M, Wesner S, Snoeck J, Ruelle J, De Bel A, Lacor P, De Munter P, Van Wijngaerden E, Zazzi M, Kaiser R, Ayouba A, Peeters M, de Oliveira T, Alcantara LC, Grossman Z, Sloot P, Otelea D, Paraschiv S, Boucher C, Camacho RJ, Vandamme AM.

Bioinformatics. 2013 Jun 1;29(11):1477-80. doi: 10.1093/bioinformatics/btt162. Epub 2013 May 2.

35.

Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response.

Vercauteren J, Beheydt G, Prosperi M, Libin P, Imbrechts S, Camacho R, Clotet B, De Luca A, Grossman Z, Kaiser R, Sönnerborg A, Torti C, Van Wijngaerden E, Schmit JC, Zazzi M, Geretti AM, Vandamme AM, Van Laethem K.

PLoS One. 2013 Apr 17;8(4):e61436. doi: 10.1371/journal.pone.0061436. Print 2013.

36.

HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure.

Sangeda RZ, Theys K, Beheydt G, Rhee SY, Deforche K, Vercauteren J, Libin P, Imbrechts S, Grossman Z, Camacho RJ, Van Laethem K, Pironti A, Zazzi M, Sönnerborg A, Incardona F, De Luca A, Torti C, Ruiz L, Van de Vijver DA, Shafer RW, Bruzzone B, Van Wijngaerden E, Vandamme AM; Virolab and EuResist Projects.

Infect Genet Evol. 2013 Oct;19:349-60. doi: 10.1016/j.meegid.2013.03.014. Epub 2013 Mar 21.

37.

Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba.

Pérez L, Kourí V, Alemán Y, Abrahantes Y, Correa C, Aragonés C, Martínez O, Pérez J, Fonseca C, Campos J, Álvarez D, Schrooten Y, Dekeersmaeker N, Imbrechts S, Beheydt G, Vinken L, Soto Y, Álvarez A, Vandamme AM, Van Laethem K.

Infect Genet Evol. 2013 Jun;16:144-50. doi: 10.1016/j.meegid.2013.02.002. Epub 2013 Feb 14.

PMID:
23416260
38.

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.

De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnerborg A, Codoñer FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration in Chain.

J Infect Dis. 2013 Apr 15;207(8):1216-20. doi: 10.1093/infdis/jit017. Epub 2013 Jan 11.

PMID:
23315324
39.

HIV-1 transmitted drug resistance in Latin America and the Caribbean: what do we know?

Pineda-Peña AC, Bello DC, Sussmann O, Vandamme AM, Vercauteren J, van Laethem K, Gómez-López A.

AIDS Rev. 2012 Oct-Dec;14(4):256-67. Review.

PMID:
23258300
40.

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.

Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DA, Albert J, Asjö B, Balotta C, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kücherer C, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Liitsola K, Schmit JC, Schuurman R, Sönnerborg A, Stanekova D, Stanojevic M, Struck D, Van Laethem K, Wensing AM, Boucher CA, Vandamme AM; SPREAD-programme.

Retrovirology. 2012 Oct 3;9:81. doi: 10.1186/1742-4690-9-81.

41.

High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba.

Kourí V, Alemán Y, Pérez L, Pérez J, Fonseca C, Correa C, Aragonés C, Campos J, Álvarez D, Schrooten Y, Dekeersmaeker N, Imbrechts S, Beheydt G, Vinken L, Pérez D, Álvarez A, Soto Y, Vandamme AM, Van Laethem K.

J Clin Virol. 2012 Dec;55(4):348-55. doi: 10.1016/j.jcv.2012.08.019. Epub 2012 Sep 13.

PMID:
22981617
42.

Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.

Cavaco-Silva J, Aleixo MJ, Van Laethem K, Faria D, Valadas E, Gonçalves Mde F, Gomes P, Vandamme AM, Cunha C, Camacho RJ; Portuguese HIV-2 Resistance Study Group.

J Antimicrob Chemother. 2013 Jan;68(1):190-2. doi: 10.1093/jac/dks363. Epub 2012 Sep 13.

PMID:
22977160
43.

HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.

Palma AC, Covens K, Snoeck J, Vandamme AM, Camacho RJ, Van Laethem K.

J Antimicrob Chemother. 2012 May;67(5):1075-9. doi: 10.1093/jac/dks010. Epub 2012 Feb 13.

PMID:
22331593
44.

Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study.

Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnerborg A, Kaiser R, Codoñer FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A; SEHERE consortium.

J Antimicrob Chemother. 2011 Aug;66(8):1886-96. doi: 10.1093/jac/dkr171. Epub 2011 May 30.

PMID:
21624929
45.

Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility.

Magiorkinis E, Paraskevis D, Detsika MG, Lu L, Magiorkinis G, Lazanas M, Imbrechts S, Van Laethem K, Vandamme AM, Pilot-Matias T, Molla A, Camacho RJ, Hatzakis A.

AIDS Res Hum Retroviruses. 2011 Nov;27(11):1223-9. doi: 10.1089/AID.2010.0275. Epub 2011 May 13.

PMID:
21417947
46.

Differences in the mannose oligomer specificities of the closely related lectins from Galanthus nivalis and Zea mays strongly determine their eventual anti-HIV activity.

Hoorelbeke B, Van Damme EJ, Rougé P, Schols D, Van Laethem K, Fouquaert E, Balzarini J.

Retrovirology. 2011 Feb 11;8(1):10. doi: 10.1186/1742-4690-8-10.

47.

Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.

Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, Van Laethem K, Alcaro S, Costa G, Tommasi C, Zaccarelli M, Narciso P, Antinori A, Ceccherini-Silberstein F, Balzarini J, Perno CF.

J Acquir Immune Defic Syndr. 2010 Nov;55(3):336-44. doi: 10.1097/QAI.0b013e3181e6763f.

PMID:
20739898
48.

Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).

Zazzi M, Kaiser R, Sönnerborg A, Struck D, Altmann A, Prosperi M, Rosen-Zvi M, Petroczi A, Peres Y, Schülter E, Boucher CA, Brun-Vezinet F, Harrigan PR, Morris L, Obermeier M, Perno CF, Phanuphak P, Pillay D, Shafer RW, Vandamme AM, van Laethem K, Wensing AM, Lengauer T, Incardona F.

HIV Med. 2011 Apr;12(4):211-8. doi: 10.1111/j.1468-1293.2010.00871.x. Epub 2010 Aug 19. Erratum in: HIV Med. 2012 Apr;13(4):253.

49.

Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape.

Theys K, Deforche K, Beheydt G, Moreau Y, van Laethem K, Lemey P, Camacho RJ, Rhee SY, Shafer RW, Van Wijngaerden E, Vandamme AM.

BMC Bioinformatics. 2010 Aug 3;11:409. doi: 10.1186/1471-2105-11-409.

50.

Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time.

Frentz D, Boucher CA, Assel M, De Luca A, Fabbiani M, Incardona F, Libin P, Manca N, Müller V, O Nualláin B, Paredes R, Prosperi M, Quiros-Roldan E, Ruiz L, Sloot PM, Torti C, Vandamme AM, Van Laethem K, Zazzi M, van de Vijver DA.

PLoS One. 2010 Jul 9;5(7):e11505. doi: 10.1371/journal.pone.0011505.

Supplemental Content

Loading ...
Support Center